TG Therapeutics stock is at critical resistance. What’s driving TGTX to record levels?
The company on Tuesday reported positive Phase 1 results for subcutaneous BRIUMVI (ublituximab-xiiy) in myasthenia gravis, with 82% of subjects hitting a minimal clinically important difference in MG-ADL and a mean improvement of over four points. Management also said it plans to start a Phase 2 trial enrolling about 120 patients, aiming to pair rapid symptom control with longer-term disease modification.In a related BRIUMVI program, TG Therapeutics previously posted positive topline results in May from the Phase 3 ENHANCE trial for a consolidated single-infusion initiation regimen in relapsing forms of multiple sclerosis, and it's targeting a supplemental FDA filing in the second half of 2026.Critical Price Levels To Watch For TGTXWednesday's surge is pushing the stock further above its trend gauges: it's trading about 20.5% above the 20-day SMA ($39.86) and 45.9% above the 200-day SMA ($32.91), which is the kind of "extended" posture that can invite volatility even in a bull trend. The bigger-picture structure is still constructive, with the 20-day SMA above the 50-day SMA and a golden cross (50-day above 200-day) that formed in April.For momentum, MACD is the cleaner lens right now: it's above its signal line with a positive histogram, which points to improving upside pressure versus the prior downswing. Practically, that means dips are more likely to get bought while MACD stays in that posture, but the stock's distance from the moving averages raises the odds of sharp pullbacks if sentiment cools.
